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The protein Par-4 acts in the cytoplasm to trigger cell death signaling via caspase activation and the 
mitochondrial release of cytochrome c. Burikhanov et al. (2009) now provide surprising evidence 
that Par-4 can also promote apoptosis from outside the cell, after its secretion in response to 
endoplasmic reticulum stress.Cell death is a highly regulated pro-
cess required during development and 
throughout the lifetime of an organism 
in order to establish and maintain the 
functional capacity and homeostasis of 
various organs and to suppress tumor 
development. The regulation of cell death 
involves coordination between numer-
ous signaling molecules, many of which 
are simultaneously involved in regulating 
cellular proliferation or survival pathways 
with tightly controlled crosstalk and feed-
back loops. Therefore, it is not surprising 
that the improper induction or malfunction 
of apoptotic cell death is manifested in a 
variety of diseases, including Alzheimer’s 
disease, autoimmune diseases, Parkin-
son’s disease, and cancer. Apoptosis is 
induced through an extrinsic pathway via 
activation of cell surface death recep-
tors or through an intrinsic mechanism 
by depolarization of the mitochondrial 
membrane potential and increased levels 
of Ca2+ ions. These result in the rapid acti-
vation of caspases 8 and 9, respectively 
(Jin and El-Deiry, 2005). Considering that 
death is imminent once caspase cleavage 
is initiated, it is of paramount importance 
that the pathways that signal cell death 
be subject to precise control. Rangnekar 
and colleagues (Burikhanov et al., 2009) 
now describe an unexpected activity for 
Par-4 (prostate apoptosis response 4), 
previously known for its intracellular roles 
in promoting cell death. They show that 
in response to endoplasmic reticulum 
stress, Par-4 has an extracellular activ-
ity via TRAIL, a ligand that triggers the 
extrinsic apoptosis pathway (Figure 1).
The regulator of apoptosis Par-4 has 
remained poorly understood, although 
in vivo data have implicated it in tumor 220 Cell 138, July 24, 2009 ©2009 Elsevier suppression (Garcia-Cao et al., 2003; 
Zhao et al., 2007). Its proapoptotic activ-
ity is attributed to the SAC (selective 
for apoptosis in cancer cells) domain, 
which is capable of nuclear transloca-
tion, caspase activation, inhibition of 
Bcl-2 expression, and downregulation 
of the transcription factor NF-kB. These 
Figure 1. A New Cell Death Pathway Involving Par-4, TRAIL, and ER Stress
Burikhanov et al. (2009) describe a new cell death signaling pathway involving the putative tumor sup-
pressor protein Par-4. They show that Par-4 is secreted and binds the ER stress chaperone protein GRP78 
at the cell surface. Moreover, Par-4 and GRP78 are shown to be essential for TRAIL-induced apoptosis 
in several human cancer cell lines. Par-4 exists in the cytoplasm, endoplasmic reticulum, and nucleus 
and can be secreted in response to ER stress, thapsigargin, and tunicamycin in a Brefeldin A-sensitive 
manner. Surprisingly, GRP78, previously known as a prosurvival protein, is involved in Par-4- and TRAIL-
induced apoptotic signaling. TRAIL binds cell surface receptors such as DR5 and DR4, which recruit 
FADD and caspase 8 in a DISC (death-inducing signaling complex) to initiate extrinsic cell death. In the 
cytoplasm, Par-4 can be regulated by the kinases Akt and ζPKC and can inhibit the transcription factor 
NFκB to promote cell death. In the nucleus, Par-4 interacts with the transcription factor WT1 to inhibit 
the antiapoptotic protein Bcl2, and Par-4 also inhibits the topoisomerase TOP1. The ER stress pathway 
through the kinase PERK regulates eukaryotic translation initiation factor eIF2a to inhibit global protein 
translation while activating specific transcription and translation through ATF4 and CHOP. GRP78/BiP 
heterodimerizes with PERK in the ER and inhibits its activity.Inc.
intracellular Par-4 functions are nega-
tively regulated by multiple mechanisms, 
including Par-4 downregulation in differ-
entiated cells such as neurons, cytoplas-
mic sequestration by Akt1, and mutations 
observed in a variety of malignancies. 
This well-established intracellular activ-
ity of Par-4 is now complemented with 
the unexpected discovery of an extracel-
lular function for Par-4.
Burikhanov et al. identify a secreted 
form of Par-4 in the culture medium of 
both normal and malignant prostate cells 
(BPH-1 and PC-3 cells, respectively) and 
in Par-4 transgenic mice in vivo. The 
authors then discover a link between 
the endoplasmic reticulum (ER) stress 
response and Par-4 secretion. ER stress 
occurs when the ER is overwhelmed by 
misfolded proteins, resulting in an over-
all decrease in protein translation and 
the activation of the glucose-regulated 
ER stress chaperone protein GRP78/
BiP. Extended ER stress can result in cell 
death by the inhibition of Bcl-2, and in 
murine cells the activation of caspase-12. 
Burikhanov et al. use exogenous agents 
to induce an ER stress response and find 
increased levels of secreted Par-4.
In an elegant series of experiments, the 
authors identify the chaperone GRP78 
as a binding partner to Par-4 (specifically 
through its SAC domain) and show that 
this interaction is capable of initiating cell 
death dependent on FADD (Fas-associ-
ated protein with death domain). FADD 
is part of the death-inducing signaling 
complex (DISC). With coimmunoprecipi-
tation, endogenous GRP78 is found to 
interact with intracellular Par-4 or its SAC 
domain. The authors hypothesize that 
GRP78 binds Par-4 prior to cell-surface 
translocation and subsequent secretion. 
Indeed, the two proteins colocalize at 
the ER under basal conditions, but after 
ER stress and prior to Par-4 secretion, 
GRP78 and Par-4 interact within cell 
surface membrane fractions. Secreted 
Par-4 subsequently induces apoptosis 
in a manner dependent on membrane-
bound GRP78.
The involvement of GRP78 is espe-
cially intriguing given the opposing roles 
for GRP78 in both cell survival and cell 
death. Moderate levels of ER stress 
induce expression of chaperone proteins 
to promote cell survival in the presence 
of proteotoxicity; however, prolonged or extreme levels of ER stress result in 
the initiation of apoptosis. Par-4 secre-
tion and its interaction with GRP78 
may indicate a switch in the function of 
GRP78, from promoting cell survival to 
promoting cell death. The enhanced cell 
survival and chemoresistance conferred 
by GRP78 have been targeted for their 
therapeutic potential in cancer (Arap et 
al., 2004; Pyrko et al., 2007). The find-
ings of Burikhanov et al. suggest that 
the proapoptotic function of GRP78 
makes it a less attractive target. In con-
trast, secreted Par-4 has tumor selective 
proapoptotic action and could represent 
a new therapeutic target for cancer.
One of the most studied and clini-
cally relevant inducers of apoptosis is 
TRAIL (tumor necrosis factor-related 
apoptosis-inducing ligand) (Ashkenazi 
and Herbst, 2008). TRAIL has also gar-
nered significant attention in the context 
of ER stress. The induction of ER stress 
increases the expression of the TRAIL 
receptor DR5, which may explain why ER 
stressors, such as the protease inhibitor 
bortezomib, sensitize cells to TRAIL-
induced apotosis (Kandasamy and 
Kraft, 2008). Enhanced TRAIL sensitivity 
has also been observed in Jurkat cells 
after Par-4 transfection (Boehrer et al., 
2006). Burikhanov et al. now show that 
Par-4 secretion is increased after treat-
ment of PC-3 prostate cancer cells with 
TRAIL, whereas Par-4 secretion is not 
increased in benign BPH-1 cells with the 
same treatment. Using neutralizing anti-
bodies for Par-4 and GRP78, the authors 
demonstrate that both secreted Par-4 
and cell surface GRP78 are required 
for TRAIL-induced apoptosis in PC-3, 
H460, or HeLa cells. The upregulation 
of Par-4 by ER stress suggests a new 
means by which cells are sensitized to 
TRAIL. Although it remains to be seen 
whether Par-4 modulation can be used 
for therapeutic benefit, these findings do 
suggest that surface expression of Par-4 
should be tested to prospectively iden-
tify TRAIL-sensitive tumors.
It is unclear how TRAIL induces 
Par-4 expression and how the interac-
tion of Par-4 and GRP78 affects TRAIL-
mediated formation of the DISC, which 
triggers caspase 8 activation, or influ-
ences the trafficking of TRAIL and its 
receptors. Because GRP78 is typically 
thought of as a prosurvival molecule, it Celwill be of interest to determine in more 
detail the impact of Par-4 and TRAIL on 
the autophosphorylation of cell mem-
brane-localized GRP78, as well as the 
impact of downstream signaling on cell 
death or survival. Studies investigating 
effects of Par-4 on the broader tumor 
necrosis factor (TNF) family will be of 
particular interest, given earlier studies 
by the Rangnekar group showing effects 
of Par-4 on Fas and FasL trafficking to 
induce apoptosis. Further studies of 
the coordinated effects of Par-4 on 
the TNF family may shed more light on 
Par-4 function in normal physiology, cell 
death, and cancer.
Tumor growth is a dynamic process 
driven by the relative contribution of 
aberrant cell proliferation signals (onco-
genes) and cell death signaling (tumor 
suppressor genes). The increased inci-
dence of spontaneous tumors in mice 
lacking Par-4 lends credence to the 
identification of Par-4 as a tumor sup-
pressor protein. Given the clear require-
ment of GRP78/BiP in embryonic 
survival (Luo et al., 2006), additional 
work, including its conditional deletion 
in somatic cells and tumors in vivo, is 
needed to further unravel its poten-
tial proapoptotic role in ER stress and 
extrinsic cell death pathways. Insensi-
tivity or acquired resistance to apop-
totic signaling contributes to the clinical 
resistance of malignant tumors to many 
standard chemotherapeutic agents. 
The use of small molecule and antibody 
therapeutics are increasingly attractive 
as alternative strategies to target resis-
tant tumors; therefore, new findings in 
the field of apoptotic regulation, such 
as those described by Burikhanov et al., 
are extremely relevant to cancer thera-
peutics. In addition to identifying new 
targets, these findings may also lead to 
the development of assays that predict 
a tumor’s response to treatment.
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The reversible, covalent addition of ubiq-
uitin to target proteins is a highly con-
served and flexible regulatory mecha-
nism. Monoubiquitination can change the 
activity of a ubiquinated target protein, 
whereas the addition of a ubiquitin chain 
can direct a protein to the 26S protea-
some for rapid proteolytic degradation. 
Many proteins are modified by ubiquitin 
or ubiquitin-like proteins through the 
activity of the well-known E1-E2-E3 
enzyme cascade, in which the E3 ubiq-
uitin ligase binds the substrate and 
recruits the ubiquitin transferase activity 
of the E2 ubiquitin-conjugating enzyme. 
In humans, more than 500 predicted E3 
ubiquitin ligases act on thousands of 
gene products and often recognize spe-
cifically modified forms of those proteins. 
Opposing this army of E3 ligases are 
?95 deubiquitinating enzymes (DUBs), 
proteases that cleave the isopeptide 
bond between the C-terminal glycine 
of ubiquitin and a side-chain lysine of a 
target protein or ubiquitin itself (Reyes-
Turcu et al., 2009). There are five distinct 
DUB domains, of which one is a metal-
loprotease (JAMM domain) and four are 
cysteine proteases (USP, OTU, MJD, 
and UCH domains). It remains gener-
ally unclear how DUBs recognize their 
substrates. We also only have a modest 
understanding of the biological roles for 
most DUBs (Nijman et al., 2005); some 
have been linked to ubiquitin processing, 
histone modification, cell-cycle and DNA 
repair, kinase signaling, and endocyto-
sis. With so much uncharted territory, 
how do we connect DUBs to their biol-
ogy? In this issue of Cell, Sowa and col-
leagues (2009) approach this problem by 
purifying and identifying by mass spec-
trometry 774 high-confidence interact-
ing proteins of 75 epitope-tagged DUBs 
(Figure 1). The authors further propose a 
standardized scoring method to quantify 
the confidence in the interactions they 
identify and to track improvements in the 
methodology itself.
The three keys to proteomic identifica-
tion of interacting proteins are the selec-
tivity of the purification, the accuracy of 
the mass spectrometric identification of 
proteins, and the bioinformatic and statis-
tical analysis of the proteomic hits. How 
do Sowa and colleagues approach these 
steps? Using a retroviral expression vec-
tor, the authors establish stable cultured 
cell lines expressing hemagglutinin (HA) 
epitope-tagged versions of the DUBs. 
The tagged “bait” protein is immunopre-
cipitated along with interacting proteins 
from extracts of the cells by resin harbor-
ing anti-HA antibodies. These interact-
ing proteins are cleaved into small frag-
ments by trypsin, and duplicate samples 
from the purification are analyzed by liq-
uid chromatography followed by tandem 
mass spectrometry (LC-MS/MS) (Figure 
1). With this standard single-epitope tag 
affinity purification scheme, substantial 
nonspecific interacting proteins are also 
isolated. These “background” interac-
tions are partially corrected for by con-
trol purifications, including those with the 
other 74 DUBs. However, this purification 
approach may be improved by using two 
independent epitope tags and thus two 
sequential affinity purification steps to 
achieve a more selective purification. 
Another powerful method of stringent 
purification involves the specific isola-
tion of correctly localized proteins in the 
cell with green fluorescent protein tags 
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Deubiquitinating enzymes (DUBs) act on ubiquitinated substrates to regulate their modification 
and stability. In this issue, Sowa et al. (2009) present a comprehensive proteomic analysis of 
DUB interacting proteins in humans and a new quantitative scoring system for hits (CompPASS), 
providing a resource that links DUBs to biological pathways.
